Maximum Price Registration for Medical Devices in Belarus

1. Key takeaways

Belarus applies a price registration system to medicines and certain medical devices, and from 2026-07-30 the function of registering the maximum ex-factory price of the manufacturer is carried out by the state agency State Pharmaceutical Supervision (Gosfarmnadzor). Before that date the function sat with the expert institution. The transfer is more than an address change on a form: it changes which institution a manufacturer must brief, which service catalogue applies and how a price file is tracked. Projects that straddle the cutover date need to confirm both where a pending application now goes and how the transition was arranged. Because the Belarusian market is dominated by state budget procurement, price registration is not an optional marketing exercise — it determines whether a registered product can be sold at all in the segment that accounts for most of the demand. The correct reading is that price registration is a second admission gate standing behind the first: registration answers whether the product may be sold; price registration answers at what price level it may be sold, and without it the commercial plan stops at the threshold.

2. Legal basis

The two top rows carry the operative change: Resolution No. 378, adopted on 2026-07-27 and effective 2026-07-30, moves the price registration function from TSEIZ to Gosfarmnadzor, and the government press office report relayed by BelTA on 2026-07-28 enumerates the transferred functions, including the registration of maximum ex-factory prices of medicines. The lower rows place the change in context: circulation stage rules under No. 177 and the statutory anchor in Article 39-1 of the Healthcare Law. Together they show both the institutional transfer and the framework within which price files continue to be processed after the transfer.

3. Expert insights

Insight one: price registration is an admission gate behind the first admission. Completing registration answers whether the product may be sold; price registration answers at what price level it may be sold. In a market with price controls, a product whose price is not registered can be on the register and still fail to generate real sales, because public purchasers and reimbursement-linked channels cannot buy at an unregistered price. Companies should treat price registration as an independent milestone in the project schedule, not as a natural continuation after registration, and should resource it accordingly.

Insight two: the practical meaning of the function transfer is a change of liaison window. No. 378 moves price registration from the expert institution to Gosfarmnadzor. For projects crossing the 2026-07-30 boundary, two confirmations are needed: which institution receives a newly filed price registration application, and how applications already under review at the time of transfer were transitioned. Assuming continuity of the old window is the obvious failure mode, and the cheapest protection is a written confirmation from the receiving institution or the local representative on where the file stands.

Insight three: price registration is strongly linked to public procurement. The Belarusian medical market is dominated by state budget procurement (see Article 38 of this series), and price registration status directly affects whether a product can participate. For companies targeting the public segment, price registration should be the first priority after registration itself, sequenced ahead of channel building, because a registered product without a registered price cannot be tendered at all.

Insight four: price changes may trigger re-registration. Whether an adjustment of the ex-factory price requires a fresh registration, and under which procedure, should be confirmed in writing with the competent authority or the local representative. A pricing decision taken without that confirmation can strand the product between an old registered price and a new commercial price, forcing a choice between selling at a level the register does not support and suspending sales while the paperwork catches up.

4. Practical recommendations

The recommendations below convert the institutional change into scheduling and governance steps.

1. List price registration as the first to-do after registration completes. Place it in the compliance calendar alongside registration rather than treating it as an ancillary matter that follows automatically.
2. Confirm the liaison window after the transfer. From 2026-07-30 submit to Gosfarmnadzor; for applications pending across the cutover, confirm the transition arrangement separately in writing.
3. Plan the pricing strategy in step with registration. Fix the pricing scheme before the price registration filing, so that repeated adjustments after registration do not destabilise the price file.
4. Confirm whether re-registration is needed before any price change. Establish a compliance review mechanism for price changes, so that every adjustment is checked against the registration duty before it takes commercial effect.

5. Verification checklist

• □ Price registration has been listed as an independent milestone after registration completion
• □ Liaison with Gosfarmnadzor after 2026-07-30 has been confirmed
• □ The transition arrangement for applications pending across the cutover has been confirmed
• □ The pricing scheme was fixed before the registration filing
• □ A compliance review mechanism for price changes has been established

Regulatory information verified as of 30 October 2026.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three areas. First, distinguishing between the applicability conditions and the remaining time windows of the two channels, the Union-wide registration and the national registration of each member state — the national registration procedure of Belarus has been fully re-routed by the Council of Ministers Resolution No. 211 of 28 April 2026 (state register number 6-1/55925, effective 2026-05-01), which compresses the total timeframe for preliminary technical work to 90 calendar days, keeps the list of such work closed, and prohibits the implementing organisation from expanding it, while the window for submitting applications under the national procedure takes 2027-12-31 as its key milestone, so route selection must be decided in step with the time window. Second, local authorised representative services: GRZAN can act as the statutory representative of a manufacturer in Belarus, undertaking registration submission, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has updated its liaison mechanisms after the Council of Ministers Resolution No. 378 of 27 July 2026 (effective 2026-07-30) transferred adverse event functions to the state agency State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN assists in establishing a quality management system that meets ISO 13485 requirements and organises technical documentation according to the target route — for the national route, per the annexes to Ministry of Health Resolution No. 55; for the Union route, per EEC Council Decision No. 46.

For business enquiries: info@grzanglobal.com